Emma McGuire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emma McGuire has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Colin Stewart Brown
London UK Health Security Agency
4 shared publications - Simon Michael Collin
Bristol Medical School, University of Bristol, Bristol, UK
4 shared publications - Simon Tiberi
Queen Mary & Bart's Health Tuberculosis Centre, Blizard Institute, Faculty of Medicine and Dentistry, QMUL, London, UK
3 shared publications - Akish Luintel
Institute of Global Health Innovation, Imperial College London, UK
2 shared publications Ang Li
United Kingdom Health Security Agency (UKHSA), London, United Kingdom
2 shared publications- Bethan Balch2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e94014
Extent of Digital Health Fragmentation and Potential Implications for Antimicrobial Prescribing: Rapid Evidence Review
Background: Prior microbiology results, resistance patterns, and antimicrobial exposure are central to safe and effective antimicrobial prescribing. Digital health fragmentation refers to the dispersal of patient data across multiple electronic systems and the associated challenge of accessing complete information at the point of care. Antimicrobial prescribing for infections represents a critical use case to investigate the impact of digital health fragmentation on patient care. While interoperability has been studied in the context of patient safety, no review has described digital health fragmentation within the United Kingdom and examined its impact on antimicrobial prescribing and antimicrobial stewardship (AMS). Objective: This study aimed to (1) characterize the extent of digital health fragmentation in the United Kingdom, (2) summarize the available evidence on its impact on AMS and prescribing practices in high-income countries, and (3) identify potential solutions. Methods: A rapid review of the peer-reviewed literature was conducted following published guidance for rapid reviews and the PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-Analyses) statement. MEDLINE ALL and PsycInfo were searched on August 19, 2025, using search terms relating to digital health fragmentation or interoperability, patient safety, and antimicrobial use. Searches were limited to English-language publications from 2015 (for characterizing the recent trends or current state of digital health fragmentation in the United Kingdom) or 2010 onward (for AMS-related impacts and solutions). Screening was conducted by 4 researchers following predefined inclusion and exclusion criteria. Extracted data were synthesized narratively through framework analysis. Study quality was appraised using the Mixed Methods Appraisal Tool. Results: Fourteen studies met the inclusion criteria. Ten studies described the extent and nature of digital health fragmentation in the United Kingdom. Digital health fragmentation affects a large number of patients and is linked to clinical care efficiency, quality, and safety risks, including limited access to external clinical records, missing or incomplete information, duplicate investigations, delays in decision‑making, and substantial time spent searching for data. Evidence specific to antimicrobial prescribing was limited (4 studies) but indicated that AMS relies on information spread across multiple systems, with poor interoperability disrupting workflows, hindering communication, and undermining stewardship activities. Only 1 study reported the development of a digital tool designed to address digital health fragmentation and support AMS. Conclusions: Digital health fragmentation negatively affects patient care across the United Kingdom, yet evidence on how it impacts AMS remains scarce. Given the urgency of the global antimicrobial resistance crisis, future research should therefore quantify the scale and impact of digital health fragmentation for AMS to inform investment and innovation in digital infrastructure and clinical-supportive solutions. Trial Registration: PROSPERO CRD420251126067; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251126067
- 6 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e94014
Open AccessExtent of Digital Health Fragmentation and Potential Implications for Antimicrobial Prescribing: Rapid Evidence Review
Background: Prior microbiology results, resistance patterns, and antimicrobial exposure are central to safe and effective antimicrobial prescribing. Digital health fragmentation refers to the dispersal of patient data across multiple electronic systems and the associated challenge of accessing complete information at the point of care. Antimicrobial prescribing for infections represents a critical use case to investigate the impact of digital health fragmentation on patient care. While interoperability has been studied in the context of patient safety, no review has described digital health fragmentation within the United Kingdom and examined its impact on antimicrobial prescribing and antimicrobial stewardship (AMS). Objective: This study aimed to (1) characterize the extent of digital health fragmentation in the United Kingdom, (2) summarize the available evidence on its impact on AMS and prescribing practices in high-income countries, and (3) identify potential solutions. Methods: A rapid review of the peer-reviewed literature was conducted following published guidance for rapid reviews and the PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-Analyses) statement. MEDLINE ALL and PsycInfo were searched on August 19, 2025, using search terms relating to digital health fragmentation or interoperability, patient safety, and antimicrobial use. Searches were limited to English-language publications from 2015 (for characterizing the recent trends or current state of digital health fragmentation in the United Kingdom) or 2010 onward (for AMS-related impacts and solutions). Screening was conducted by 4 researchers following predefined inclusion and exclusion criteria. Extracted data were synthesized narratively through framework analysis. Study quality was appraised using the Mixed Methods Appraisal Tool. Results: Fourteen studies met the inclusion criteria. Ten studies described the extent and nature of digital health fragmentation in the United Kingdom. Digital health fragmentation affects a large number of patients and is linked to clinical care efficiency, quality, and safety risks, including limited access to external clinical records, missing or incomplete information, duplicate investigations, delays in decision‑making, and substantial time spent searching for data. Evidence specific to antimicrobial prescribing was limited (4 studies) but indicated that AMS relies on information spread across multiple systems, with poor interoperability disrupting workflows, hindering communication, and undermining stewardship activities. Only 1 study reported the development of a digital tool designed to address digital health fragmentation and support AMS. Conclusions: Digital health fragmentation negatively affects patient care across the United Kingdom, yet evidence on how it impacts AMS remains scarce. Given the urgency of the global antimicrobial resistance crisis, future research should therefore quantify the scale and impact of digital health fragmentation for AMS to inform investment and innovation in digital infrastructure and clinical-supportive solutions. Trial Registration: PROSPERO CRD420251126067; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251126067
- Open Access
- 23 February 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Digital health fragmentation and patient safety outcomes with respect to antimicrobial prescribing: A rapid evidence review (Preprint)
BACKGROUND Prior microbiology results, resistance patterns, and antimicrobial exposure are central to safe and effective antimicrobial prescribing. Digital health fragmentation refers to the dispersal of patient data across multiple electronic systems and the associated challenge of accessing complete information at the point of care. Antimicrobial prescribing for infections represents a critical use case to investigate the impact of digital health fragmentation on patient care. While interoperability has been studied in the context of patient safety, no review has described digital health fragmentation within the UK and examined its impact on antimicrobial prescribing and antimicrobial stewardship (AMS). OBJECTIVE To (1) characterise the extent of digital health fragmentation in the UK, (2) summarise the available evidence on its impact on AMS and prescribing practices, and (3) identify potential solutions. METHODS A rapid review of the peer-reviewed literature was conducted following published guidance for rapid reviews and the PRISMA statement. MEDLINE ALL and PsycInfo were searched on 19 August 2025 using search terms relating to digital health fragmentation/interoperability, patient safety, and antimicrobial use. Searches were limited to English-language publications from 2015 (for characterising the recent trends/current state of digital health fragmentation in the UK) or 2010 onwards (for AMS-related impacts and solutions). Screening was conducted by four researchers following pre-defined inclusion and exclusion criteria. Extracted data were synthesised narratively through framework analysis. Study quality was appraised using the Mixed Methods Appraisal Tool. RESULTS Fourteen studies met the inclusion criteria. Ten studies described the extent and nature of digital health fragmentation in the UK. Digital health fragmentation affects a large number of patients and is linked to clinical care efficiency, quality and safety risks, including limited access to external clinical records, missing or incomplete information, duplicate investigations, delays in decision‑making, and substantial time spent searching for data. Evidence specific to antimicrobial prescribing was limited (four studies) but indicated that AMS relies on information spread across multiple systems, with poor interoperability disrupting workflows, hindering communication, and undermining stewardship activities. Only one study reported the development of a digital tool designed to address digital health fragmentation and support stewardship. CONCLUSIONS Digital health fragmentation negatively affects patient care across the UK, yet evidence on which specific aspects of fragmentation most undermine antimicrobial stewardship remains scarce. AMS represents a critical use case to understand how and why digital health fragmentation has detrimental impacts on patient safety and the need for investment and innovation. Given the urgency of the global antimicrobial resistance crisis, future research should therefore quantify the scale and impact of fragmentation for AMS to direct investment and innovation in digital infrastructure and clinical-supportive solutions. CLINICALTRIAL PROSPERO (CRD420251126067)
- 23 February 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDigital health fragmentation and patient safety outcomes with respect to antimicrobial prescribing: A rapid evidence review (Preprint)
BACKGROUND Prior microbiology results, resistance patterns, and antimicrobial exposure are central to safe and effective antimicrobial prescribing. Digital health fragmentation refers to the dispersal of patient data across multiple electronic systems and the associated challenge of accessing complete information at the point of care. Antimicrobial prescribing for infections represents a critical use case to investigate the impact of digital health fragmentation on patient care. While interoperability has been studied in the context of patient safety, no review has described digital health fragmentation within the UK and examined its impact on antimicrobial prescribing and antimicrobial stewardship (AMS). OBJECTIVE To (1) characterise the extent of digital health fragmentation in the UK, (2) summarise the available evidence on its impact on AMS and prescribing practices, and (3) identify potential solutions. METHODS A rapid review of the peer-reviewed literature was conducted following published guidance for rapid reviews and the PRISMA statement. MEDLINE ALL and PsycInfo were searched on 19 August 2025 using search terms relating to digital health fragmentation/interoperability, patient safety, and antimicrobial use. Searches were limited to English-language publications from 2015 (for characterising the recent trends/current state of digital health fragmentation in the UK) or 2010 onwards (for AMS-related impacts and solutions). Screening was conducted by four researchers following pre-defined inclusion and exclusion criteria. Extracted data were synthesised narratively through framework analysis. Study quality was appraised using the Mixed Methods Appraisal Tool. RESULTS Fourteen studies met the inclusion criteria. Ten studies described the extent and nature of digital health fragmentation in the UK. Digital health fragmentation affects a large number of patients and is linked to clinical care efficiency, quality and safety risks, including limited access to external clinical records, missing or incomplete information, duplicate investigations, delays in decision‑making, and substantial time spent searching for data. Evidence specific to antimicrobial prescribing was limited (four studies) but indicated that AMS relies on information spread across multiple systems, with poor interoperability disrupting workflows, hindering communication, and undermining stewardship activities. Only one study reported the development of a digital tool designed to address digital health fragmentation and support stewardship. CONCLUSIONS Digital health fragmentation negatively affects patient care across the UK, yet evidence on which specific aspects of fragmentation most undermine antimicrobial stewardship remains scarce. AMS represents a critical use case to understand how and why digital health fragmentation has detrimental impacts on patient safety and the need for investment and innovation. Given the urgency of the global antimicrobial resistance crisis, future research should therefore quantify the scale and impact of fragmentation for AMS to direct investment and innovation in digital infrastructure and clinical-supportive solutions. CLINICALTRIAL PROSPERO (CRD420251126067)
- Open Access
- 28 November 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (11) , 002098
The role of molecular diagnostics in pleural empyema: insights from a 4-year analysis of microbial trends and antimicrobial use
Introduction. Pleural empyema is common but microbiological diagnosis is challenging, often leading to prolonged empiric broad-spectrum antimicrobial use. Hypothesis. 16S rRNA PCR on operative pleural tissue will increase diagnostic yield and improve antibiotic stewardship in patients with surgically managed pleural empyema. Aim. The objective was to characterize the clinical and microbiological characteristics of surgically managed pleural empyema, assess the diagnostic yield of 16S rRNA PCR and determine its impact on antimicrobial use. Methodology. This retrospective study identified patients with pleural empyema at a tertiary thoracic referral unit in North London, UK, between March 2019 and March 2023. Demographic, clinical and microbiological characteristics were collected. Results. One hundred eighty-three patients underwent surgery for pleural empyema at University College Hospital at Westmoreland Street over a 4-year period. Most empyemas were community-acquired, and the main surgical modality was minimally invasive video-assisted thoracoscopic surgery (151/183, 82.5%). Thirty-day all-cause post-operative mortality was 0.6%. Microbial aetiology was ascertained in 47%, with Streptococcus anginosus group, Streptococcus pneumoniae and anaerobes most frequently identified. Operative pleural tissue 16S rRNA PCR had a high diagnostic yield compared to conventional culture alone (68.2% vs. 26.4%). Post-operatively, antibiotics were prescribed for a median of 14 days (interquartile range 10–18), the majority broad spectrum (169/181, 93.4%). 16S PCR impacted antimicrobial prescribing in one-tenth of cases when used (4/32, 12.5%); however, turnaround times limited its impact. Conclusion. Molecular diagnostics improve bacterial detection and antibiotic stewardship in pleural empyema. Streamlining molecular diagnostics pathways or developing pleural-specific multiplex PCR panels could further enhance management.
- 28 November 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (11) , 002098
Open AccessThe role of molecular diagnostics in pleural empyema: insights from a 4-year analysis of microbial trends and antimicrobial use
Introduction. Pleural empyema is common but microbiological diagnosis is challenging, often leading to prolonged empiric broad-spectrum antimicrobial use. Hypothesis. 16S rRNA PCR on operative pleural tissue will increase diagnostic yield and improve antibiotic stewardship in patients with surgically managed pleural empyema. Aim. The objective was to characterize the clinical and microbiological characteristics of surgically managed pleural empyema, assess the diagnostic yield of 16S rRNA PCR and determine its impact on antimicrobial use. Methodology. This retrospective study identified patients with pleural empyema at a tertiary thoracic referral unit in North London, UK, between March 2019 and March 2023. Demographic, clinical and microbiological characteristics were collected. Results. One hundred eighty-three patients underwent surgery for pleural empyema at University College Hospital at Westmoreland Street over a 4-year period. Most empyemas were community-acquired, and the main surgical modality was minimally invasive video-assisted thoracoscopic surgery (151/183, 82.5%). Thirty-day all-cause post-operative mortality was 0.6%. Microbial aetiology was ascertained in 47%, with Streptococcus anginosus group, Streptococcus pneumoniae and anaerobes most frequently identified. Operative pleural tissue 16S rRNA PCR had a high diagnostic yield compared to conventional culture alone (68.2% vs. 26.4%). Post-operatively, antibiotics were prescribed for a median of 14 days (interquartile range 10–18), the majority broad spectrum (169/181, 93.4%). 16S PCR impacted antimicrobial prescribing in one-tenth of cases when used (4/32, 12.5%); however, turnaround times limited its impact. Conclusion. Molecular diagnostics improve bacterial detection and antibiotic stewardship in pleural empyema. Streamlining molecular diagnostics pathways or developing pleural-specific multiplex PCR panels could further enhance management.
- Open Access
- 15 November 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (2) , 399-404
A case of penicillin-resistant group B Streptococcus isolated from a patient in the UK
Objectives: In England, group B streptococci (GBS; Streptococcus agalactiae) are considered universally susceptible to penicillin. Reports from Africa, Asia, North America and a few European countries have described GBS isolates with penicillin MICs above the epidemiological cut-off (0.125 mg/L). Our aim was to characterize a penicillin-resistant GBS (PRGBS) isolate recovered in 2016 from a patient treated with long-term antimicrobials in the UK. Methods: Antibiotic susceptibility of a referred isolate from a discharging sinus overlying a chronic prosthetic joint infection was determined using gradient strip testing for seven antibiotics. Illumina short read sequencing was carried out using a HiSeq 2500 platform to determine MLST, capsular type, to detect mutations in the pbp genes, and to compare the isolate with contemporaneous GBS isolates circulating in the UK. Results: The GBS isolate belonged to capsular type Ia and MLST 144. We observed resistance to penicillin (MIC = 1 mg/L) and tetracycline (32 mg/L) with susceptibility to linezolid (1 mg/L), erythromycin (0.064 mg/L), clindamycin (0.064 mg/L), teicoplanin (0.064 mg/L) and vancomycin (0.25 mg/L). Deduced amino acid sequences revealed substitutions and non-synonymous changes in PBP2x and PBP2b. Genomic analysis of contemporaneous cases (n = 34) from across the UK identified single nucleotide polymorphism (SNP) variation ranged from 153–6596 SNPs. Conclusions: We confirm the first identification of a PRGBS isolate amongst referrals to the UK’s national reference laboratory. Substitutions in pbp1a, pbp2a, pbp2x and pbp2b were identified that likely developed in the face of long-term beta-lactam antibiotic use.
- 15 November 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (2) , 399-404
Open AccessA case of penicillin-resistant group B Streptococcus isolated from a patient in the UK
Objectives: In England, group B streptococci (GBS; Streptococcus agalactiae) are considered universally susceptible to penicillin. Reports from Africa, Asia, North America and a few European countries have described GBS isolates with penicillin MICs above the epidemiological cut-off (0.125 mg/L). Our aim was to characterize a penicillin-resistant GBS (PRGBS) isolate recovered in 2016 from a patient treated with long-term antimicrobials in the UK. Methods: Antibiotic susceptibility of a referred isolate from a discharging sinus overlying a chronic prosthetic joint infection was determined using gradient strip testing for seven antibiotics. Illumina short read sequencing was carried out using a HiSeq 2500 platform to determine MLST, capsular type, to detect mutations in the pbp genes, and to compare the isolate with contemporaneous GBS isolates circulating in the UK. Results: The GBS isolate belonged to capsular type Ia and MLST 144. We observed resistance to penicillin (MIC = 1 mg/L) and tetracycline (32 mg/L) with susceptibility to linezolid (1 mg/L), erythromycin (0.064 mg/L), clindamycin (0.064 mg/L), teicoplanin (0.064 mg/L) and vancomycin (0.25 mg/L). Deduced amino acid sequences revealed substitutions and non-synonymous changes in PBP2x and PBP2b. Genomic analysis of contemporaneous cases (n = 34) from across the UK identified single nucleotide polymorphism (SNP) variation ranged from 153–6596 SNPs. Conclusions: We confirm the first identification of a PRGBS isolate amongst referrals to the UK’s national reference laboratory. Substitutions in pbp1a, pbp2a, pbp2x and pbp2b were identified that likely developed in the face of long-term beta-lactam antibiotic use.
- Open Access
- 14 June 2024
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 45, 100656
Invasive Trichoderma longibrachiatum infection in a neutropaenic patient
- 14 June 2024
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 45, 100656
Open AccessInvasive Trichoderma longibrachiatum infection in a neutropaenic patient
- Open Access
- 29 February 2024
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 31 (6)
The immune status of migrant populations in Europe and implications for vaccine-preventable disease control: a systematic review and meta-analysis
Background: Ensuring vaccination coverage reaches established herd immunity thresholds (HITs) is the cornerstone of any vaccination programme. Diverse migrant populations in European countries have been associated with cases of vaccine-preventable diseases (VPDs) and outbreaks, yet it is not clear to what extent they are an under-immunized group. Methods: We did a systematic review and meta-analysis to synthesize peer-reviewed published primary research reporting data on the immune status of migrants in EU/EEA countries, the UK and Switzerland, calculating their pooled immunity coverage for measles, mumps, rubella and diphtheria using random-effects models. We searched on Web of Science, Embase, Global Health and MEDLINE (1 January 2000 to 10 June 2022), with no language restrictions. The protocol is registered with PROSPERO (CRD42018103666). Findings: Of 1103 abstracts screened, 62 met eligibility criteria, of which 39 were included in the meta-analysis. The meta-analysis included 75 089 migrants, predominantly from outside Europe. Pooled immunity coverage among migrant populations was well below the recommended HIT for diphtheria (n = 7, 57.4% [95% confidence interval (CI): 43.1–71.7%] I2 = 99% vs HIT 83–86%), measles (n = 21, 83.7% [95% CI: 79.2–88.2] I2 = 99% vs HIT 93–95%) and mumps (n = 8, 67.1% [95% CI: 50.6–83.6] I2 = 99% vs HIT 88–93%) and midway for rubella (n = 29, 85.6% [95% CI: 83.1–88.1%] I2 = 99% vs HIT 83–94%), with high heterogeneity across studies. Interpretation: Migrants in Europe are an under-immunized group for a range of important VPDs, with this study reinforcing the importance of engaging children, adolescents and adults in ‘catch-up’ vaccination initiatives on arrival for vaccines, doses and boosters they may have missed in their home countries. Co-designing strategies to strengthen catch-up vaccination across the life course in under-immunized groups is an important next step if we are to meet European and global targets for VPD elimination and control and ensure vaccine equity.
- 29 February 2024
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 31 (6)
Open AccessThe immune status of migrant populations in Europe and implications for vaccine-preventable disease control: a systematic review and meta-analysis
Background: Ensuring vaccination coverage reaches established herd immunity thresholds (HITs) is the cornerstone of any vaccination programme. Diverse migrant populations in European countries have been associated with cases of vaccine-preventable diseases (VPDs) and outbreaks, yet it is not clear to what extent they are an under-immunized group. Methods: We did a systematic review and meta-analysis to synthesize peer-reviewed published primary research reporting data on the immune status of migrants in EU/EEA countries, the UK and Switzerland, calculating their pooled immunity coverage for measles, mumps, rubella and diphtheria using random-effects models. We searched on Web of Science, Embase, Global Health and MEDLINE (1 January 2000 to 10 June 2022), with no language restrictions. The protocol is registered with PROSPERO (CRD42018103666). Findings: Of 1103 abstracts screened, 62 met eligibility criteria, of which 39 were included in the meta-analysis. The meta-analysis included 75 089 migrants, predominantly from outside Europe. Pooled immunity coverage among migrant populations was well below the recommended HIT for diphtheria (n = 7, 57.4% [95% confidence interval (CI): 43.1–71.7%] I2 = 99% vs HIT 83–86%), measles (n = 21, 83.7% [95% CI: 79.2–88.2] I2 = 99% vs HIT 93–95%) and mumps (n = 8, 67.1% [95% CI: 50.6–83.6] I2 = 99% vs HIT 88–93%) and midway for rubella (n = 29, 85.6% [95% CI: 83.1–88.1%] I2 = 99% vs HIT 83–94%), with high heterogeneity across studies. Interpretation: Migrants in Europe are an under-immunized group for a range of important VPDs, with this study reinforcing the importance of engaging children, adolescents and adults in ‘catch-up’ vaccination initiatives on arrival for vaccines, doses and boosters they may have missed in their home countries. Co-designing strategies to strengthen catch-up vaccination across the life course in under-immunized groups is an important next step if we are to meet European and global targets for VPD elimination and control and ensure vaccine equity.
- Open Access
- 5 February 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (6) , 1443-1450
Community-Acquired Staphylococcus aureus Bacteremia Among People Who Inject Drugs: A National Cohort Study in England, 2017–2020
People who inject drugs (PWID) are at increased risk of community-acquired Staphylococcus aureus bacteremia (CA-SAB), but little is known about clinical outcomes of CA-SAB in PWID compared with the wider population of patients with CA-SAB. Three national datasets were linked to provide clinical and mortality data on patients hospitalized with CA-SAB in England between 1 January 2017 and 31 December 2020. PWID were identified using the International Classification of Diseases, Tenth Revision code for “mental health and behavioral disorder due to opioid use” (F11). Multivariable logistic regression was used to estimate adjusted odds ratios (aORs) for associations of PWID with 30-day all-cause mortality and 90-day hospital readmission. In 10 045 cases of CA-SAB, 1612 (16.0%) were PWID. Overall, 796 (7.9%) patients died within 30 days of CA-SAB admission and 1189 (11.8%) patients were readmitted to hospital within 90 days of CA-SAB. In those without infective endocarditis, there was strong evidence of lower odds of mortality among PWID compared with non-PWID (aOR, 0.47 [95% confidence interval {CI}: .33–.68]; P < .001), whereas there was no association in CA-SAB case fatality with endocarditis (aOR, 1.40 [95% CI: .87–2.25]; P = .163). PWID were less likely to be readmitted within 90 days of CA-SAB (aOR, 0.79 [95% CI: .65–.95]; P = .011). In this large cohort study of patients with CA-SAB in England, PWID had lower odds of death in the absence of endocarditis and lower odds of readmission within 90 days compared to non-PWID patients. This study highlights the overrepresentation of PWID among patients with CA-SAB nationally.
- 5 February 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (6) , 1443-1450
Open AccessCommunity-Acquired Staphylococcus aureus Bacteremia Among People Who Inject Drugs: A National Cohort Study in England, 2017–2020
People who inject drugs (PWID) are at increased risk of community-acquired Staphylococcus aureus bacteremia (CA-SAB), but little is known about clinical outcomes of CA-SAB in PWID compared with the wider population of patients with CA-SAB. Three national datasets were linked to provide clinical and mortality data on patients hospitalized with CA-SAB in England between 1 January 2017 and 31 December 2020. PWID were identified using the International Classification of Diseases, Tenth Revision code for “mental health and behavioral disorder due to opioid use” (F11). Multivariable logistic regression was used to estimate adjusted odds ratios (aORs) for associations of PWID with 30-day all-cause mortality and 90-day hospital readmission. In 10 045 cases of CA-SAB, 1612 (16.0%) were PWID. Overall, 796 (7.9%) patients died within 30 days of CA-SAB admission and 1189 (11.8%) patients were readmitted to hospital within 90 days of CA-SAB. In those without infective endocarditis, there was strong evidence of lower odds of mortality among PWID compared with non-PWID (aOR, 0.47 [95% confidence interval {CI}: .33–.68]; P < .001), whereas there was no association in CA-SAB case fatality with endocarditis (aOR, 1.40 [95% CI: .87–2.25]; P = .163). PWID were less likely to be readmitted within 90 days of CA-SAB (aOR, 0.79 [95% CI: .65–.95]; P = .011). In this large cohort study of patients with CA-SAB in England, PWID had lower odds of death in the absence of endocarditis and lower odds of readmission within 90 days compared to non-PWID patients. This study highlights the overrepresentation of PWID among patients with CA-SAB nationally.
- Open Access
- 25 April 2023
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 72 (4) , 001683
Is Panton–Valentine leucocidin (PVL) toxin associated with poor clinical outcomes in patients with community-acquired Staphylococcus aureus bacteraemia?
Introduction. Panton–Valentine leucocidin (PVL) toxin is a potential determinant of virulence associated with S. aureus infection. Gap Statement. The contribution of PVL to S. aureus pathogenicity remains unclear. Aim. To compare clinical outcomes in hospitalized patients with PVL-positive and PVL-negative community-acquired (CA) S. aureus bacteraemia. Methods. Three national datasets were combined to provide clinical and mortality data for patients with CA S. aureus blood culture isolates sent to the UK reference laboratory for PVL testing, August 2018 to August 2021. Multivariable logistic regression models were built for the effect of PVL positivity on 30 day all-cause mortality and 90 day readmission. Results. In 2191 cases of CA S. aureus bacteraemia, there was no association between PVL and mortality (adjusted odds ratio, aOR: 0·90, 95 % confidence interval, CI: 0·50–1·35, P=0·602) and no difference in median LOS (14 versus 15 days, P=0.169). PVL-positive cases had lower odds of readmission (aOR 0·74, CI 0·55–0.98, P=0·038). There was no evidence that MRSA status modified this effect (P=0·207). Conclusions. In patients with CA S. aureus bacteraemia PVL toxin detection was not associated with worse outcomes.
- 25 April 2023
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 72 (4) , 001683
Open AccessIs Panton–Valentine leucocidin (PVL) toxin associated with poor clinical outcomes in patients with community-acquired Staphylococcus aureus bacteraemia?
Introduction. Panton–Valentine leucocidin (PVL) toxin is a potential determinant of virulence associated with S. aureus infection. Gap Statement. The contribution of PVL to S. aureus pathogenicity remains unclear. Aim. To compare clinical outcomes in hospitalized patients with PVL-positive and PVL-negative community-acquired (CA) S. aureus bacteraemia. Methods. Three national datasets were combined to provide clinical and mortality data for patients with CA S. aureus blood culture isolates sent to the UK reference laboratory for PVL testing, August 2018 to August 2021. Multivariable logistic regression models were built for the effect of PVL positivity on 30 day all-cause mortality and 90 day readmission. Results. In 2191 cases of CA S. aureus bacteraemia, there was no association between PVL and mortality (adjusted odds ratio, aOR: 0·90, 95 % confidence interval, CI: 0·50–1·35, P=0·602) and no difference in median LOS (14 versus 15 days, P=0.169). PVL-positive cases had lower odds of readmission (aOR 0·74, CI 0·55–0.98, P=0·038). There was no evidence that MRSA status modified this effect (P=0·207). Conclusions. In patients with CA S. aureus bacteraemia PVL toxin detection was not associated with worse outcomes.
- Open Access
- 13 April 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (15) , 2200573
Time to negative throat culture following initiation of antibiotics for pharyngeal group A Streptococcus: a systematic review and meta-analysis up to October 2021 to inform public health control measures
Background: Public health guidance recommending isolation of individuals with group A streptococcal (GAS) infection or carriage for 12–24 h from antibiotic initiation to prevent onward transmission requires a strong evidence base. Aim: To estimate the pooled proportion of individuals who remain GAS culture-positive at set intervals after initiation of antibiotics through a systematic literature review (PROSPERO CRD42021290364) and meta-analysis. Methods: We searched Ovid MEDLINE (1946–), EMBASE (1974–) and Cochrane library. We included interventional or observational studies with ≥ 10 participants reporting rates of GAS throat culture positivity during antibiotic treatment for culture-confirmed GAS pharyngitis, scarlet fever and asymptomatic pharyngeal GAS carriage. We did not apply age, language or geographical restrictions. Results: Of 5,058 unique records, 43 were included (37 randomised controlled studies, three non-randomised controlled trials and three before-and-after studies). The proportion of individuals remaining culture-positive on day 1, day 2 and days 3–9 were 6.9% (95% CI: 2.7–16.8%), 5.4% (95% CI: 2.1–13.3%) and 2.6% (95% CI: 1.6–4.2%). For penicillins and cephalosporins, day 1 positivity was 6.5% (95% CI: 2.5–16.1%) and 1.6% (95% CI: 0.04–42.9%), respectively. Overall, for 9.1% (95% CI: 7.3–11.3), throat swabs collected after completion of therapy were GAS culture-positive. Only six studies had low risk of bias. Conclusions: Our review provides evidence that antibiotics for pharyngeal GAS achieve a high rate of culture conversion within 24 h but highlights the need for further research given methodological limitations of published studies and imprecision of pooled estimates. Further evidence is needed for non-beta-lactam antibiotics and asymptomatic individuals.
- 13 April 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (15) , 2200573
Open AccessTime to negative throat culture following initiation of antibiotics for pharyngeal group A Streptococcus: a systematic review and meta-analysis up to October 2021 to inform public health control measures
Background: Public health guidance recommending isolation of individuals with group A streptococcal (GAS) infection or carriage for 12–24 h from antibiotic initiation to prevent onward transmission requires a strong evidence base. Aim: To estimate the pooled proportion of individuals who remain GAS culture-positive at set intervals after initiation of antibiotics through a systematic literature review (PROSPERO CRD42021290364) and meta-analysis. Methods: We searched Ovid MEDLINE (1946–), EMBASE (1974–) and Cochrane library. We included interventional or observational studies with ≥ 10 participants reporting rates of GAS throat culture positivity during antibiotic treatment for culture-confirmed GAS pharyngitis, scarlet fever and asymptomatic pharyngeal GAS carriage. We did not apply age, language or geographical restrictions. Results: Of 5,058 unique records, 43 were included (37 randomised controlled studies, three non-randomised controlled trials and three before-and-after studies). The proportion of individuals remaining culture-positive on day 1, day 2 and days 3–9 were 6.9% (95% CI: 2.7–16.8%), 5.4% (95% CI: 2.1–13.3%) and 2.6% (95% CI: 1.6–4.2%). For penicillins and cephalosporins, day 1 positivity was 6.5% (95% CI: 2.5–16.1%) and 1.6% (95% CI: 0.04–42.9%), respectively. Overall, for 9.1% (95% CI: 7.3–11.3), throat swabs collected after completion of therapy were GAS culture-positive. Only six studies had low risk of bias. Conclusions: Our review provides evidence that antibiotics for pharyngeal GAS achieve a high rate of culture conversion within 24 h but highlights the need for further research given methodological limitations of published studies and imprecision of pooled estimates. Further evidence is needed for non-beta-lactam antibiotics and asymptomatic individuals.
- Open Access
Time to negative throat culture following initiation of antibiotics for pharyngeal group A Streptococcus : a systematic review and meta-analysis to inform public health control measures
Background Public health guidance recommending isolation of individuals with group A streptococcal (GAS) infection or carriage for 12-24 hours from antibiotic initiation to prevent onward transmission requires a strong evidence-base. Methods We conducted a systematic review (PROSPERO CRD42021290364) and meta-analysis to estimate the pooled proportion of individuals who remain GAS culture-positive at set intervals after initiation of antibiotics. We searched Ovid MEDLINE (1946-), EMBASE (1974-) and the Cochrane library. We included interventional or observational studies with ten or more participants reporting rates of GAS throat culture during antibiotics for culture confirmed GAS pharyngitis, scarlet fever, and asymptomatic pharyngeal GAS carriage. We did not apply age, language, or geographical restrictions. Findings Of 5,058 unique records identified, 43 were included; 37 (86%) randomised controlled studies, three (7%) non-randomised controlled trials and three (7%) before-and-after studies. The proportion of individuals who remained culture-positive at day 1, day 2, and day 3-9 were 6.9% (95% CI 2.7-16.8%), 5.4% (95% CI 2.1-13.3%) and 2.6% (95% CI 1.6-4.2%). For penicillins and cephalosporins, day 1 positivity was 6.5% (95% CI 2.5-16.1%) and 1.6% (95% CI 0.04-42.9%) respectively. Overall, for 9.1% (95% CI 7.3-11.3), throat swabs collected after completion of therapy were GAS culture-positive. Interpretation Our review provides evidence that antibiotics for pharyngeal GAS achieve a high rate of culture conversion within 24 hours but highlights the need for further research given the methodological limitations of published studies and imprecision of pooled estimates. Further evidence is needed for non-beta-lactam antibiotics and for asymptomatic individuals.
Open AccessTime to negative throat culture following initiation of antibiotics for pharyngeal group A Streptococcus : a systematic review and meta-analysis to inform public health control measures
Background Public health guidance recommending isolation of individuals with group A streptococcal (GAS) infection or carriage for 12-24 hours from antibiotic initiation to prevent onward transmission requires a strong evidence-base. Methods We conducted a systematic review (PROSPERO CRD42021290364) and meta-analysis to estimate the pooled proportion of individuals who remain GAS culture-positive at set intervals after initiation of antibiotics. We searched Ovid MEDLINE (1946-), EMBASE (1974-) and the Cochrane library. We included interventional or observational studies with ten or more participants reporting rates of GAS throat culture during antibiotics for culture confirmed GAS pharyngitis, scarlet fever, and asymptomatic pharyngeal GAS carriage. We did not apply age, language, or geographical restrictions. Findings Of 5,058 unique records identified, 43 were included; 37 (86%) randomised controlled studies, three (7%) non-randomised controlled trials and three (7%) before-and-after studies. The proportion of individuals who remained culture-positive at day 1, day 2, and day 3-9 were 6.9% (95% CI 2.7-16.8%), 5.4% (95% CI 2.1-13.3%) and 2.6% (95% CI 1.6-4.2%). For penicillins and cephalosporins, day 1 positivity was 6.5% (95% CI 2.5-16.1%) and 1.6% (95% CI 0.04-42.9%) respectively. Overall, for 9.1% (95% CI 7.3-11.3), throat swabs collected after completion of therapy were GAS culture-positive. Interpretation Our review provides evidence that antibiotics for pharyngeal GAS achieve a high rate of culture conversion within 24 hours but highlights the need for further research given the methodological limitations of published studies and imprecision of pooled estimates. Further evidence is needed for non-beta-lactam antibiotics and for asymptomatic individuals.